Finance entity
All 1 tracked stories fall under one category: earnings. Dr. Michael Yu is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Their average consequence score of 5 runs below the beat's 5.6 for that window.
Last mentioned: 2h ago
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: earnings. Dr. Michael Yu is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Their average consequence score of 5 runs below the beat's 5.6 for that window. Each story carries 2 original sources on average, compared with 2.3 for the broader beat in this window. We currently track 1 Finance story that mention Spero Therapeutics, Inc., all published on August 25, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 23 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Spero Therapeutics, Inc.. Shared-story counts are live from our verified record — not editorial picks.
For investors, Innovent's H1 2026 update is a story of transformation and deal-driven optionality: RMB10B+ revenue already achieved, 20+ partnered assets, and partnerships with MNCs. But exact H1 numbers remain undisclosed in the release, so treat growth claims with caution.
Spero Therapeutics, Inc. is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
